AnPac Bio-Medical Science Co. Ltd.
| NASDAQ: ANPC | Healthcare / Biotechnology / China |
| 4.37 | -0.2499 | -5.41% | Vol 35.70K | 1Y Perf 1 402.23% |
| May 19th, 2023 15:59 DELAYED |
| BID | 4.19 | ASK | 4.65 | ||
| Open | 4.57 | Previous Close | 4.62 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 8.00 | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ☆ — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | — | |
| Market Cap | 24.68M | Earnings Date | 30th May 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.30 | |
| Beta | 1.56 |
Today's Price Range 4.254.65 | 52W Range 2.6011.99 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | - | ||
| 6 Months | -34.97% | ||
| 1 Year | 1 402.23% | ||
| 3 Years | -6.62% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 1.05K | |||
ROE last 12 Months | 5.56K | |||
ROA (5Y Avg) | -90.44 | |||
ROA last 12 Months | -149.53 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -330.69 | |||
Return on invested Capital Q | -457.36 | |||
Return on invested Capital Y | -222.04 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 5.77 | ||||
| 6.65 | ||||
| - | ||||
| -0.70 | ||||
| -8.25 | ||||
| -16.99 | ||||
| -0.24 | ||||
| 11.32M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 0.70 | ||||
| 0.42 | ||||
| 1.38 | ||||
| -255.60 | ||||
| Leverage Ratio | 12.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 78.60 | ||||
| -660.20 | ||||
| -660.20 | ||||
| -692.90 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.63M | ||||
| 0.89 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | - | -0.34 | - |
| Q01 2021 | - | -0.37 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 35.70K |
| Shares Outstanding | 83.11K |
| Shares Float | 5.65M |
| Trades Count | 211 |
| Dollar Volume | 160.36K |
| Avg. Volume | 32.57K |
| Avg. Weekly Volume | 49.51K |
| Avg. Monthly Volume | 27.55K |
| Avg. Quarterly Volume | 20.64K |
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) stock closed at 4.37 per share at the end of the most recent trading day (a -5.41% change compared to the prior day closing price) with a volume of 35.70K shares and market capitalization of 363.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 111 people. AnPac Bio-Medical Science Co. Ltd. CEO is Chris Chang Yu.
The one-year performance of AnPac Bio-Medical Science Co. Ltd. stock is 1402.23%, while year-to-date (YTD) performance is -6.62%. ANPC stock has a five-year performance of %. Its 52-week range is between 2.6 and 11.99, which gives ANPC stock a 52-week price range ratio of %
AnPac Bio-Medical Science Co. Ltd. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 5.77, a price-to-sale (PS) ratio of 6.65, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -149.53%, a ROC of -330.69% and a ROE of 5 559.40%. The company’s profit margin is -%, its EBITDA margin is -660.20%, and its revenue ttm is $1.63 Million , which makes it $0.89 revenue per share.
Of the last four earnings reports from AnPac Bio-Medical Science Co. Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AnPac Bio-Medical Science Co. Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for AnPac Bio-Medical Science Co. Ltd. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AnPac Bio-Medical Science Co. Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AnPac Bio-Medical Science Co. Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AnPac Bio-Medical Science Co. Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.61, ATR14 : 0.76, CCI20 : -112.85, Chaikin Money Flow : -0.19, MACD : -0.31, Money Flow Index : 6.39, ROC : -12.60, RSI : 37.53, STOCH (14,3) : 3.61, STOCH RSI : 0.00, UO : 39.38, Williams %R : -96.39), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AnPac Bio-Medical Science Co. Ltd. in the last 12-months were:
AnPac Bio-Medical Science Co. Ltd.
AnPac Bio-Medical Science Co Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative, patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence.
CEO: Chris Chang Yu
Telephone: +86 57820516666
Address: 801 Bixing Street, Lishui 323006, , CN
Number of employees: 111
